摘要
目的研究护理干预对美罗华(Rituximab)联合CHOP(R-CHOP)治疗B细胞性非霍奇金淋巴瘤临床疗效及不良反应的影响。方法选取2012年1月~2014年1月我院诊断为B细胞性非霍奇金淋巴瘤患者41例,随机分为对照组20例和观察组21例。对照组给予常规护理,观察组在常规护理的基础上给予护理干预措施,比较4个疗程后两组患者的疗效、不良反应发生率、护理满意度和生活质量评分。结果观察组患者病情缓解率高于对照组,但差异无统计学意义(P> 0.05),观察组不良反应发生率低于对照组,其中恶心呕吐及脱发发生率差异有统计学意义(P <0.05)。观察组护理满意度和生活质量评分高于对照组,差异有统计学意义(P <0.05)。结论护理干预措施有助于降低部分不良反应的发生,提高护理满意度和患者的生存质量。
Objective To explore the effects of nursing intervention on clinical effects and adverse reactions of rituximab combined with CHOP(R-CHOP) in treating B-cell non-Hodgkin lymphoma. Methods 41 patients who were diagnosed as B-cell non-Hodgkin lymphoma in our hospital from January 2012 to January 2014 were selected. They were randomly divided into the control group(20 cases) and the observation group(21 cases). The control group was given routine nursing while the observation group was given nursing intervention based on routine nursing. The curative effects, incidence of adverse reaction, nursing satisfaction and quality of life score were compared between those two groups after four treatment courses. Results The remission rate of observation group was higher than that of control group, however, the difference was not statistically significant(P > 0.05). The incidence of adverse reaction of observation group was lower than that of control group, and the difference in the incidence of nausea, vomiting and hair loss was statistically significant(P < 0.05). The nursing satisfaction and quality of life score of observation group was significantly higher than that of the control group. The difference was statistically significant(P < 0.05). Conclusion Nursing intervention measures could reduce the occurrence of adverse reaction and improve nursing satisfaction and quality of life of patients.
作者
赵立丽
刘丹
窦勤玲
闫文婷
ZHAO Lili;LIU Dan;DOU Qinling;YAN Wenting(Department of Hematology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China)
出处
《中国医药科学》
2019年第23期155-157,共3页
China Medicine And Pharmacy
关键词
美罗华
B细胞性非霍奇金淋巴瘤
护理干预措施
满意度
生存质量
疗效
Rituximab
B-cell non-Hodgkin lymphoma
Nursing intervention measures
Satisfaction
Quality of life
Curative effects
